>

Incyte Profile

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>INC</div>

Performance

0 / 100

Odds of Distress

Analyze Filter   Check how we calculate scores
Equity ratings for Incyte Corporation are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 24, 2019 and ending today February 22, 2020. Click here to learn more.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company was founded in 1991 and is headquartered in Wilmington, Delaware. Incyte operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 1456 people. more on Incyte
Incyte Fama & French Business Services
Business Services
Fama & French Classification
Incyte SEC Filings
Incyte SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameIncyte Corporation
Older SymbolICY
ChairmanHerve HoppenotView All
Thematic Classification
Currently Active Investing Idea
  Biotech
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Incyte
Piotroski F Score
Academic score to determine the current strength of Incyte financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
Incyte ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Long Term Debt to Equity
Debt to Equity Ratio
Return on Investment
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Average Bond Rating: N/ANot Rated
Profitability
Few selected profitability drivers of Incyte representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
Net Income Per Employee
Operating Margin
EBITDA Margin
Gross Margin
Profit Margin
Incyte Corporation (INCY) is traded on BATS Exchange in USA. It is located in 1801 Augustine Cut Off, Wilmington, DE 19803, United States and employs 1,456 people. Incyte Corporation was previously known as Incyte Corp and was traded on BATS Exchange under the symbol ICY. Incyte is listed under Business Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 15.74 B. Incyte conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 215.4 M outstanding shares of which 3.98 M shares are currently shorted by private and institutional investors with about 2.31 trading days to cover. INCYTE CORP currently holds about 1.99 B in cash with 662.88 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.22.
Check Incyte Probability Of Bankruptcy

Ownership Allocation (%)

Incyte Target Price Odds Analysis

Odds Below 82.42HorizonTargetOdds Above 82.42
40.40%30 days 82.42 59.45%
Based on normal probability distribution, the odds of Incyte to move above current price in 30 days from now is about 59.45 (This Incyte Corporation probability density function shows the probability of Incyte Stock to fall within a particular range of prices over 30 days) .

Incyte Top Holders

Incyte Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Baker Bros Advisors LpCommon Shares32 M2.8 B
Blackrock IncCommon Shares15.2 M1.3 B
View Incyte Diagnostics

Incyte Corporation Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Incyte Against Markets

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Incyte Corporate Filings

Incyte SEC Reporting

Financial Statements and Exhibits. Results of Operations and Financial Condition
Unclassified Corporate Event
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Other Events

Incyte Corporate Directors

Paul Friedman Director
Jacqualyn Fouse Director
Paul Clancy Director
Please see Risk vs Return Analysis. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Company logos by clearbit